-
US panel backs trendy peptides despite safety concerns
-
WNBA viral star Cunningham wades into trans athletes row
-
Justice Dept withdraws NY Times subpoenas over Trump plane report
-
Hearn dismisses Fury talk of Joshua no-show for super fight
-
Barcelona's De Jong returns from World Cup with torn ligament
-
'Like a war zone': France evacuates 20,000 due to wildfires
-
Albania police teargas protesters against Trump-linked resort
-
Ships avoid Ukrainian grain ports after Russian attacks
-
US panel says to loosen restrictions on popular peptide despite safety concerns
-
Oil passes $100 a barrel again: why it's more serious this time
-
Verstappen swerves around future questions
-
Who are the six candidates vying to lead the UN?
-
EU renews online child sex abuse detection powers
-
Hamilton proud of recovery after hitting rock bottom a year ago
-
Airbus, Boeing fly in different directions at Farnborough
-
Carapaz eyes polkadot mountains jersey after stage win
-
Bab al-Mandeb Strait: another key oil shipping route under threat
-
Fields medal awarded to four young mathematicians
-
Deadly wildfires in Europe force thousands to flee
-
Carapaz claims Tour de France stage as Pogacar loses key team-mate
-
NATO to overhaul European fuel pipeline network
-
Alonso welcomes Aston Martin upgrade, warns against unreal expectations
-
US trade envoy to make tariff announcement as 10% duty soon expires
-
Anderson declares Man City 'kings of Manchester' after £116 mn move
-
Trump stuns Saudis by pinning nuclear deal to Israel ties
-
Relieved Russell says Mercedes have solved his power problems mystery
-
Tough day for Ubisoft stock topped with weaker revenues
-
Oil soars above $100 as Middle East fears grow
-
Swelling jet fuel costs hit American Airlines outlook
-
Venezuelans turn to scrap collecting in quake-hit beach 'paradise'
-
Carapaz climbs unopposed to Tour de France 18th stage win
-
Heptathlon champion Johnson-Thompson joins list of Commonwealth Games absentees
-
Sooryavanshi hits maiden 50 as India thump Zimbabwe in T20
-
Nigeria's Dangote raises $2.5bn to expand Africa's largest refinery
-
ECB opens door to September rate-hike as Iran war flares up
-
Oil soars to $100 on fresh Mideast attacks
-
World Bank estimates Venezuela quakes caused $19.6 bn in damage
-
Coal-fired power generation rising globally on Mideast war: IEA
-
Italy's far-right line up to defend jeweller who killed robbers
-
Premier League champions Arsenal sign Greece winger Tzolis from Brugge
-
AI-led boom in IPOs raises concerns about a bust
-
French Jewish DJ sues after activists disrupt gig: lawyer
-
Klopp expected to be named new Germany coach on Friday
-
Venice film festival promises Pattinson, Oasis and Musk doc
-
ECB holds rates as Iran war flare-up threatens to drive prices higher
-
ASEAN calls for open straits as US-Iran war casts shadow
-
MEXC's "Kickoff Fest" Trading Event Concludes with Top Individual Reward of 27,352 USDT
-
Ford and Geely to form joint venture at struggling Spain plant
-
Oil soars close to $100 on fresh Mideast attacks
-
Russia warns US against Ukraine arms sales in Manila meeting
Decade since Ebola, Sierra Leone fights another deadly fever
Rummaging in the darkness of a tiny mud and thatch home in eastern Sierra Leone, ecologist James Koninga plucks a metal rat trap from under a collapsed bedframe.
The 62-year-old belongs to a group of researchers tracking the deadly Lassa fever, a viral haemorrhagic illness endemic in several West African countries and transmitted by infected rats.
Koninga knows all too well what is at stake -- he spent a gruelling 20 days in hospital with a Lassa-induced fever, headache and diarrhoea as a young researcher 30 years ago.
"I thought I was going away, I was going to die," he said.
Ten years ago, the haemorrhagic Ebola virus devastated this region, killing over 11,000 people across Guinea, Sierra Leone and Liberia.
Sierra Leone has not recorded an Ebola case since the outbreak ended in 2016, thanks partly to a vaccine rollout.
In Kenema district, an early Ebola epicentre, scientists are using the lessons learned a decade ago to try to stop Lassa fever in its tracks.
With an overall fatality rate of one percent, Lassa is nowhere near as deadly as Ebola, which kills on average 50 percent of sufferers, according to the World Health Organization.
But one in five Lassa infections can result in severe illness with a fatality rate of 15 percent.
While cases have largely plateaued in Sierra Leone, researchers are seeing a spread beyond traditional Lassa hotspots.
There is no licensed vaccine and only limited treatment, with the scars of Ebola preventing many from seeking early life-saving help.
- Living with rats -
Monitoring the rodent population is crucial in remote villages like Mapuma, where some 20 houses lie enveloped by dense forest.
"Rats burrow inside the houses for shelter," explained Koninga, donning a face shield and gloves.
Humans usually contract Lassa virus after having contact with the urine, saliva or droppings of infected rats.
"If people come in from the bush with cuts on them and lie on the bed, they could be infected."
Proximity to the forest, rudimentary mud construction, and uncovered grain and water storage make the dwellings "five-star hotels" for rats, said Lansana Kanneh, 58, field supervisor at the region's Kenema Government Hospital (KGH).
"Food is scarce for these people so sometimes they even eat the food that has been partially eaten by the rodent," he added.
Trappers can find up to 20 rats per day in some villages.
After identifying if the rodents are the Lassa-carrying Mastomys variety, samples are collected for analysis.
The rats then receive an injection that prevents viral transmission before being released.
Lassa virus infects between 100,000 and 300,000 people annually in West Africa, killing roughly 5,000, according to the Africa Centres for Disease Control and Prevention.
But the figures likely underestimate the true scale given surveillance challenges.
Admissions to the Lassa unit at KGH -- Sierra Leone's only dedicated treatment centre -– have declined in the past decade.
Patients normally arrive in the 14-bed isolation ward during the dry season from November to May, but this once-predictable pattern is increasingly uncertain.
- 'Lassa blood' -
"Now we see cases year-round," said Donald Grant, head of the KGH Lassa fever programme.
The team are also noticing Lassa beyond traditionally endemic zones, with Grant suspecting an improvement in testing as well as deforestation driving rodents into closer contact with humans.
Over the past decade, KGH has also seen an alarming uptick in Lassa patient mortality, which now stands at over 50 percent.
"We've seen a lot of these cases coming in in their late stages," said Kanneh.
"Sometimes they only spend 24 to 48 hours in the hospital, and they die."
Rapid detection is the key to survival, but non-specific febrile symptoms mean Lassa is commonly misdiagnosed as malaria, cholera or typhoid.
Hours-long journeys on dirt roads prevent many from seeking treatment.
As does the trauma from Ebola, which killed some 4,000 Sierra Leoneans.
"The community people thought that Ebola was brought by the health workers," Kanneh said, explaining that a lingering mistrust contributed to reduced admissions.
A KGH team raises awareness in local communities about seeking rapid help and ensuring good domestic hygiene.
It is a message well-received by Musa Mosoh, a 53-year-old Lassa survivor who lost seven family members to the illness.
As the morning rain fell in his village of Panguma -- a Lassa red zone -- Mosoh recalled how his family had faced stigma from the community.
"Now... people have got the understanding we are not from Lassa blood, it's just a sickness."
Mosoh tells those with a continuous fever or headache to go straight to the hospital, and even keeps cats to repel any virus-carrying rodents.
Grant, the doctor, is hopeful of a vaccine in the next few years.
Participants in Nigeria and Liberia are currently being given the first-ever Lassa vaccine to reach phase two trials -- the midway point of testing in humans.
But Grant still urges caution.
Ebola "taught us a lesson that we need not wait until that critical moment that it overwhelms all of us," he said.
"We need to act now."
H.Seidel--BTB